使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet first-quarter 2026 earnings conference call. (Operator Instructions). As a reminder, this conference is being recorded today, April 28, 2026.
各位女士、先生,早安,歡迎參加 Zimmer Biomet 2026 年第一季財報電話會議。(接線員指示)提醒各位,本次會議將於今日 2026 年 4 月 28 日錄音。
Following today's presentation, there will be a question-and-answer session. (Operator Instructions) I would now like to turn the conference over to David DeMartino, Senior Vice President, Investor Relations. Please go ahead.
在今天的簡報之後,將進行問答環節。(接線員指示)現在我想把會議交給投資人關係資深副總裁 David DeMartino。請開始。
David DeMartino - Senior Vice President, Investor Relations
David DeMartino - Senior Vice President, Investor Relations
Thank you, operator. Good morning, everyone. Welcome to Zimmer Biomet's first-quarter 2026 earnings conference call. Joining me on today's call are Ivan Tornos, our Chairman, President, and CEO; and Suky Upadhyay, our CFO, and EVP, Finance, Operations, and Supply Chain.
謝謝接線員。各位早安。歡迎參加 Zimmer Biomet 2026 年第一季財報電話會議。今天與我一同出席的有:我們的董事長、總裁暨執行長 Ivan Tornos;以及我們的財務長兼執行副總裁(財務、營運與供應鏈)Suky Upadhyay。
Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For details and discussions that involve these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our SEC filings. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially.
在開始之前,我想提醒各位,我們在本次電話會議中的評論將包含前瞻性陳述。由於各種風險與不確定性,實際結果可能與前瞻性陳述所示有重大差異。關於這些風險與不確定性的細節與討論,以及此類前瞻性陳述固有的限制,請參閱我們向 SEC 提交的文件。請注意,即使實際結果或未來預期發生重大變化,我們亦不承擔更新這些前瞻性陳述的義務。
Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation on these measures to most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our first-quarter earnings release, which can be found on our website, zimmerbiomet.com.
此外,本次電話會議的討論將包含若干非 GAAP 財務衡量指標,其中部分為前瞻性的非 GAAP 財務衡量指標。這些指標與最直接可比的 GAAP 財務衡量指標之調節,以及我們計算這些指標的依據說明,已包含於我們的第一季財報新聞稿中,可於我們的網站 zimmerbiomet.com 查閱。
With that, I'll turn the call over to Ivan. Ivan?
接下來,我把電話交給 Ivan。Ivan?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Good morning, everyone, and thank you for joining today's call. I would like to start, as I always do, by sharing my gratitude to our Zimmer Biomet team members around the world. Your determination, your discipline, and your dedication to customers and patients are what moves our business and our mission forward. We're off to a strong start for the year, strategically, operationally, and financially, and that momentum is a direct reflection of the strength of our team, the resilience of our business, and the impact that we can have where we stay focused on innovating and executing for our customers. Once again, my sincere thanks to the Zimmer Biomet team members.
各位早安,感謝各位參加今天的電話會議。我想一如既往先分享我對全球 Zimmer Biomet 團隊成員的感謝。你們的決心、紀律,以及對客戶與病患的投入,推動了我們的業務與使命向前邁進。我們在今年開局強勁,無論在策略、營運或財務面皆是如此,而這股動能直接反映了我們團隊的實力、業務的韌性,以及當我們專注於為客戶創新並落實執行時所能帶來的影響。再次向 Zimmer Biomet 的團隊成員致上我誠摯的感謝。
During my prepared remarks this morning, I'm going to cover four key areas. First, I'll start by summarizing our first-quarter results. Second, I will provide an update on our US go-to-market changes. Third, I will discuss our 2026 outlook. And then lastly, I'll briefly cover the progress that we continue to make across the three key strategic priorities of the company, those being people and culture, operational excellence, and innovation, and diversification.
在我今天上午的準備發言中,我將涵蓋四個重點領域。第一,我會先總結我們第一季的業績。第二,我將更新我們在美國的市場進入(go-to-market)變革。第三,我將討論我們對 2026 年的展望。最後,我會簡要說明我們在公司三大關鍵策略優先事項上的持續進展,分別是:人才與文化、營運卓越,以及創新與多元化。
Starting with the first-quarter results. I'm proud of how the team began the year, making strong progress to our 2026 sales growth commitments, EPS, and free cash flow commitments. In the first quarter, we grew sales 2.9% on an organic constant currency basis at the upper end of our annual 2026 revenue guidance range. And we delivered adjusted EPS of $2.09, which was up 15% year over year. Notably, the first quarter saw a $0.20 benefit from tariff-related items relative to our expectations.
先從第一季業績談起。我為團隊在年初的表現感到自豪,我們在達成 2026 年銷售成長承諾、EPS 與自由現金流承諾方面取得了強勁進展。第一季我們在有機、固定匯率基礎上,銷售成長 2.9%,位於我們 2026 年全年營收指引區間的上緣。我們也交出調整後 EPS 2.09 美元,年增 15%。值得注意的是,第一季相較於我們原先預期,關稅相關項目帶來 0.20 美元的正面貢獻。
As we get into the details of these results, unless otherwise noted, all statements on this call will be about the first quarter of 2026 high compared to the same period in 2025 and all commentary would be on a constant currency and adjusted operating basis. First-quarter 2026 organic constant currency commentary excludes the impact from the Paragon 28 acquisition, which we closed in April of 2025.
在進一步說明這些結果之前,除非另有說明,本次電話會議中的所有陳述皆指 2026 年第一季相較於 2025 年同期,且所有評論皆以固定匯率與調整後營運基礎呈現。2026 年第一季的有機固定匯率評論不包含 Paragon 28 併購的影響;該交易已於 2025 年 4 月完成。
Looking at the first-quarter results in more detail, our US business increased 3.2% while International grew 2.5%. These results reflect healthy end markets, strong technology sales, which once again grew in strong double-digit rates and continued momentum from our recently launched new products. Importantly, this performance was against the backdrop of changes to our go-to-market strategies in both the US and some designated international markets.
更詳細來看第一季業績,我們的美國業務成長 3.2%,國際業務成長 2.5%。這些結果反映了健康的終端市場、強勁的科技產品銷售(再次以強勁的兩位數成長),以及我們近期新產品上市所帶來的持續動能。重要的是,這些表現是在我們於美國及部分指定國際市場調整市場進入策略的背景下達成的。
US knee growth of 2.2% in the quarter reflects a greater than 20% increase in partial knee cells driven by our Oxford Partial Cementless Knee, the only partial cementless knee on the market in the United States. This performance was partially offset by pressure in our legacy [total] knee implants, such as NextGen and Vanguard, which we continue to phase out as part of our brand rationalization strategy. International Knees grew 1.3% for the quarter. Our US hip franchise grew 5% in the quarter as we are seeing increasing traction of our hip triple play of one which now represents nearly 40% of our US [Hips temps], OrthoGrid, or AI-based [hip] navigation platform, a HAMMR or surgical impact.
本季美國膝關節業務成長 2.2%,反映部分膝關節(partial knee)銷量成長超過 20%,主要由我們的 Oxford Partial Cementless Knee 帶動;該產品是美國市場上唯一的部分無骨水泥膝關節產品。此表現部分被我們傳統的[全]膝關節植入物(如 NextGen 與 Vanguard)所承受的壓力所抵銷;我們仍在依品牌精簡策略逐步淘汰這些產品。國際膝關節本季成長 1.3%。我們的美國髖關節事業本季成長 5%,因為我們看到髖關節「三重組合」的採用度持續提升,其中之一目前已占我們美國[髖關節 temps]近 40%;此外還包括 OrthoGrid(AI 驅動的[髖]導航平台)以及 HAMMR(手術衝擊器)。
International hip sales increased by 1%. While still early in its launch, we are seeing rapid adoption in Japan, the second largest market for Zimmer Biomet, or for first of the [warm] iodine core hip implant, which is designed to help address the risk of periprosthetic joint infection after total joint replacement.
國際髖關節銷售成長 1%。雖然仍處於上市初期,我們在日本(Zimmer Biomet 的第二大市場)看到快速採用,針對[warm] iodine core 髖關節植入物的採用正在加速;該產品旨在協助降低全關節置換後發生假體周圍關節感染(periprosthetic joint infection)的風險。
Our technology and data, bone cement, and surgical business grew nearly 12% in the quarter. Our strategy of offering a comprehensive suite of technology solutions is paying dividends. As we are seeing continued strong ROSA and TMINI sales across the board. To further this one-stop shop approach at the American Academy of Orthopedic Surgeons in March in New Orleans, we hosted technical evaluations of mBôs or fully autonomous AI-driven orthopedic robotic system, which we acquired via the Monogram acquisition.
我們的科技與數據、骨水泥以及手術業務本季成長接近 12%。我們提供完整科技解決方案組合的策略正在帶來成果,因為我們看到 ROSA 與 TMINI 的銷售持續全面強勁。為了進一步推動這種一站式(one-stop shop)做法,我們在 3 月於紐奧良舉行的美國骨科醫師學會(AAOS)年會上,舉辦了 mBôs(完全自主、AI 驅動的骨科機器人系統)的技術評估;該系統是我們透過 Monogram 併購取得的。
Surgeon feedback was overwhelmingly positive as the potential gains in safety, efficiency, ease of use, reproducibility and accuracy resonated very strongly with the customers that we engage. We recently completed enrollment in our 102-patient clinical study, we continue to expect US approval and the launch of the semiautonomous version in early 2027, followed by the fully autonomous version in late 2027 or early 2028.
外科醫師的回饋極為正面,因為在安全性、效率、易用性、可重複性與精準度方面的潛在提升,與我們互動的客戶產生了非常強烈的共鳴。我們近期已完成 102 名病患臨床研究的收案;我們仍預期於 2027 年初取得美國核准並推出半自主版本,之後於 2027 年底或 2028 年初推出完全自主版本。
In anticipation of the mBôs launch, we're increasing the number of robotic clinical sales representatives targeting to hire over 200 by the end of 2027. Finally, SCP growth of 1.6% was once again led by our US CMFT and Upper Extremities businesses, partially offset by continued challenges in restorative therapies and in our Trauma business.
為迎接 mBôs 上市,我們正增加機器人臨床銷售代表的人數,目標在 2027 年底前聘用超過 200 人。最後,SCP 本季成長 1.6%,再次由我們的美國 CMFT 與上肢(Upper Extremities)業務帶動,但部分被修復性治療(restorative therapies)以及我們創傷(Trauma)業務持續面臨的挑戰所抵銷。
Double-digit CMFT growth in the US was driven by our external closure franchise which continues to perform very nicely above market. Upper Extremities increased upper-single digits in the US as both our OsseoFit Stemless Shoulder and our Identity total shoulder platform continued to gain momentum.
美國 CMFT 的兩位數成長,主要由我們的外固定(external closure)產品線帶動,該產品線持續優於市場、表現良好。美國上肢業務成長高個位數,因為我們的 OsseoFit 無柄肩關節(Stemless Shoulder)以及 Identity 全肩關節平台持續累積動能。
Moving on now to discuss the US go-to market changes. In the US, the transition to a dedicated and specialized sales channel is progressing as planned. While the quarter did see some modest disruption, it was in line with our expectations, and importantly, we are seeing rapid increases in productivity in those territories that we have transitioned.
接下來談美國市場進入(go-to-market)變革。在美國,轉型為專責且專業化的銷售通路正按計畫推進。雖然本季確實出現一些輕微干擾,但符合我們的預期;更重要的是,我們在已完成轉型的區域看到生產力快速提升。
We remain on track to complete the transition by the end of 2027. Internationally, the evolution of our go-to-market models, particularly in emerging markets, is ongoing and also is performing in accordance to the plan and the expectations that we had. While we did see an impact on growth in the quarter, this was very much accounted for internally.
我們仍按進度預計在 2027 年底前完成轉型。在國際市場方面,我們市場進入模式的演進(特別是在新興市場)仍在進行中,且表現也符合我們的計畫與原先預期。雖然本季我們確實看到對成長的影響,但這在內部早已充分納入考量。
While our commercial changes are progressing as planned, given that it is still early in the year, we are maintaining our full-year 2026 organic constant currency revenue growth guidance of 1% to 3%, with growth roughly consistent throughout the remainder of 2026. Instead of this, our assumption of up to 100 basis points of price erosion is unchanged. We continue to anticipate an approximate 50 basis points FX tailwind to full-year revenue growth with the second quarter being a bit neutral at current rates and Paragon 28 to contribute around 100 basis points to reported sales growth in 2026 before being reflected in organic growth.
雖然我們的商業變革正按計畫推進,但鑑於目前仍在年初,我們維持 2026 年全年有機固定匯率營收成長指引 1% 至 3% 不變,且預期 2026 年剩餘期間的成長大致保持一致。與此同時,我們對價格侵蝕最高達 100 個基點的假設亦維持不變。我們仍預期匯率對全年營收成長帶來約 50 個基點的順風;以目前匯率水準來看,第二季影響將較為中性。此外,Paragon 28 預計在 2026 年對報告口徑(reported)銷售成長貢獻約 100 個基點,之後才會反映於有機成長中。
As a result, our reported sales guidance also remains unchanged at 2.5% and to 4.5% for the full year. We now expect 2026 operating margins to be better than anticipated, down slightly less than 50 basis points from 2025, which still contemplates lower gross margins, dilution from the Paragon 28 acquisition, and increased investments in our US commercial channel. We anticipate operating margins in the second quarter of 2026 being down roughly 200 basis points from the second quarter of 2025. And the third quarter, operating margins being down around 50 basis points sequentially from the second quarter.
因此,我們所公布的銷售指引也維持不變,全年為 2.5% 至 4.5%。我們現在預期 2026 年的營業利益率將優於先前預期,較 2025 年僅小幅下降、降幅略低於 50 個基點;此仍納入較低的毛利率、Paragon 28 收購帶來的稀釋效應,以及我們在美國商業通路增加投資。我們預期 2026 年第二季的營業利益率將較 2025 年第二季約下降 200 個基點;而第三季的營業利益率則預期較第二季按季約下降 50 個基點。
Our guidance for interest expense, tax rate, and end-of-year shares outstanding, which we continue to assume up to $750 million of share repurchases remains unchanged. Given these dynamics, we are raising both our EPS and free cash flow growth expectations for the year 2026. We now expect adjusted EPS to be $8.40 to $8.55 from the previous guide of $8.30 to $8.45. And we expect our free cash flow growth to be in the range of 9% to 11% versus the previous guide of 8% to 10%.
我們對利息費用、稅率以及年底流通在外股數的指引(我們仍假設最多進行 7.5 億美元的庫藏股回購)維持不變。基於這些動態,我們上調 2026 年全年 EPS 與自由現金流成長預期。我們目前預期調整後 EPS 為 8.40 至 8.55 美元,先前指引為 8.30 至 8.45 美元;我們也預期自由現金流成長將落在 9% 至 11% 的區間,相較先前指引的 8% 至 10%。
As I said, all in, the year is off to a very strong start, and I could not be any prouder or excited about what the remainder of 2026 is going to bring to Zimmer Biomet. Turning now towards three key strategic priorities for the company, people and culture are being number one; operational excellence, number two; innovation and diversification, number three.
如我所說,整體而言,今年開局非常強勁;對於 2026 年剩餘時間將為 Zimmer Biomet 帶來的一切,我感到無比自豪且興奮。接下來談公司三項關鍵策略優先事項:第一是人才與文化;第二是營運卓越;第三是創新與多元化。
People and culture remain the key competitive differentiator for Zimmer Biomet. And we continue to focus on placing the right talent in the roles to advance our strategy. With that in mind, I'm very pleased to share that Dr. Jonathan Vigdorchik, our renowned surgeon from the hospital for special surgery has joined Zimmer Biomet as Chief Science Technology and Medical Affairs Officer reporting to me. In this role, Dr. Vigdorchik will lead the strategy, delivery, and management of our global portfolio spanning AI-enabled robotics, software and data, smart implants, and connected technologies while also overseeing or global medical education.
人才與文化仍是 Zimmer Biomet 的關鍵競爭差異化因素。我們持續專注於將合適的人才配置在能推進我們策略的職位上。基於此,我很高興分享:來自特殊外科醫院(Hospital for Special Surgery)的知名外科醫師 Jonathan Vigdorchik 博士已加入 Zimmer Biomet,擔任首席科學、技術與醫療事務長(Chief Science Technology and Medical Affairs Officer),並向我匯報。在此職務中,Vigdorchik 博士將領導我們涵蓋 AI 賦能機器人、軟體與數據、智慧植入物與連網技術的全球產品組合之策略、交付與管理,同時也將監督我們的全球醫學教育。
On our second priority of operational excellence, we continue to make great strides in improving operating efficiency through expanding our manufacturing footprint into lower-cost geographies. In addition, we're making very meaningful progresses on reducing working capital by lowering our days of inventory on hand while at the same time accelerating a very robust SKU rationalization program. We expect these combined efforts to strengthen our industry-leading margins while meaningfully continue to improve our free cash flow conversion rates.
在第二項優先事項「營運卓越」方面,我們持續透過將製造版圖擴展至成本較低的地區,在提升營運效率上取得重大進展。此外,我們也在降低營運資金方面取得非常顯著的進展:一方面降低庫存持有天數(days of inventory on hand),同時加速推動一項非常強勁的 SKU 精簡(rationalization)計畫。我們預期這些合併努力將強化我們業界領先的利潤率,同時持續大幅提升自由現金流轉換率。
On pillar number three, from an innovation perspective, we recently committed to becoming the exclusive orthopedic investor in the Mobility Revolution Fund, a musculoskeletal venture capital fund launched through our collaboration between Deerfield Management and the Hospital for Special Surgery in New York City. This is going to give us the opportunity to invest in technology that has the potential to truly change the standard of care from AI data applications to cartilage repair solutions.
在第三支柱「創新」方面,我們近期承諾成為 Mobility Revolution Fund 的獨家骨科投資人;該基金是一支肌肉骨骼領域的創投基金,係透過我們與 Deerfield Management 以及紐約市特殊外科醫院(Hospital for Special Surgery)的合作而成立。這將讓我們有機會投資於具備真正改變照護標準潛力的技術,從 AI 數據應用到軟骨修復解決方案。
Speaking of the latter, we're also teaming up with some of the world's leading researchers in this groundbreaking opportunity. It is inspiring to see how rapidly we're advancing our commitment to solving some of the key problems in orthopaedics, whether it's awareness, safety, efficiency, and outcomes today and in the future.
談到後者,我們也正與全球一些頂尖研究人員攜手合作,把握這項突破性的機會。看到我們如此快速地推進對解決骨科領域若干關鍵問題的承諾,令人振奮——無論是當下與未來的認知、安 全、效率與治療結果。
Lastly, on diversification, our recent acquisitions are all seeing positive momentum. Paragon 28 first-quarter growth accelerated around 200 basis points from the fourth quarter of 2025 and is trending back towards double-digit growth performance. OrthoGrid delivered its strongest quarter to date, with significant growth and accelerated adoption, solidifying OrthoGrid as a core driver of our digital ecosystem and anterior hip triple play.
最後,在多元化方面,我們近期的收購案都呈現正向動能。Paragon 28 第一季成長較 2025 年第四季加速約 200 個基點,並正回到雙位數成長表現的趨勢。OrthoGrid 則繳出迄今最強勁的一季,成長顯著且採用加速,鞏固 OrthoGrid 作為我們數位生態系與前側髖關節 triple play 的核心驅動因素。
Finally, with enrollment complete in the Monogram clinical study, we remain on track to bring this very exciting first-to-the-world technology to market. In conclusion, we are very proud of the progress that we're makeing so far in 2026. We continue to prioritize our go-to-market commercial transformation in the US, and we continue to focus on driving robust adoption of our new product-innovation cycle.
此外,隨著 Monogram 臨床研究完成收案(enrollment),我們仍按計畫推進,將這項令人振奮、全球首創(first-to-the-world)的技術推向市場。總結而言,我們對 2026 年迄今所取得的進展深感自豪。我們持續將重點放在美國市場的上市策略(go-to-market)商業轉型,同時也持續專注於推動我們新一輪產品創新週期的強勁採用。
Before I turn the call over, I want to comment on the announcement that we made this morning regarding Suky's decision to leave Zimmer Biomet for a new opportunity in the biotechnology space. For nearly seven years, Suky has been a value partner and disciplined operator, helping us in improving our Vanguard-weighted average market growth rate profile through organic and inorganic portfolio optimization driving a top-quartile margin profile for Zimmer Biomet, strengthening the balance sheet, and significantly improving the free cash flow conversion and growth. I'm thankful for his leadership and contributions and I wish him continued success in his next chapter. Above all, I'm thankful for his friendship, which I know will continue for many years to come.
在我把電話會議交出去之前,我想就我們今天早上發布的公告做些說明:Suky 決定離開 Zimmer Biomet,前往生技領域的新機會。近七年來,Suky 一直是具價值的夥伴與嚴謹的經營者,協助我們透過有機與無機的產品組合優化,改善我們以 Vanguard 加權平均市場成長率(Vanguard-weighted average market growth rate)為基礎的成長輪廓,推動 Zimmer Biomet 達到同業前段班的利潤率輪廓,強化資產負債表,並顯著提升自由現金流轉換與成長。我感謝他的領導與貢獻,並祝福他在下一段旅程持續成功。最重要的是,我感謝他的友誼,我相信這份情誼在未來多年仍會延續。
During this transition, Paul Stellato, our current Controller, Chief Accounting Officer and Head of Corporate FP&A, will serve as Interim Chief Financial Officer. Paul is a seasoned business leader bringing more than 20 years of financial and IR, Investor Relations experience to the role. Since he joined Zimmer Biomet in 2022, Paul has been instrumental in translated our strategy into disciplined capital allocation, including our share repurchase program and recent acquisitions as well as leading the creation of global search services around the world.
在此過渡期間,我們現任財務控管長(Controller)、首席會計長(Chief Accounting Officer)暨企業 FP&A(財務規劃與分析)主管 Paul Stellato,將擔任代理首席財務長(Interim Chief Financial Officer)。Paul 是資深的企業領導者,擁有超過 20 年的財務與 IR(投資人關係,Investor Relations)經驗。自 2022 年加入 Zimmer Biomet 以來,Paul 在將我們的策略轉化為嚴謹的資本配置方面扮演關鍵角色,包括我們的庫藏股回購計畫與近期收購案;同時也領導建立全球搜尋服務(global search services)於世界各地的相關工作。
I'm extremely confident that he is the right leader at the right time, and I'm confident he will provide a steady direction and leadership as we continue to conduct a search for a successor, and I look forward to our continued partnership.
我非常有信心他是在對的時間、最合適的領導者;我也相信在我們持續尋找接任者的過程中,他將提供穩健的方向與領導。我期待我們持續合作。
With that, let me turn the call over to Suky. Thank you.
接下來,我把電話會議交給 Suky。謝謝。
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Thank you, Ivan, and good morning, everyone. I'm proud of what we've accomplished together over the past seven years. I believe Zimmer Biomet has a clear strategy and meaningful opportunity ahead. I would also like to take a minute to thank the entire Zimmer Biomet organization for all of the hard work and dedication that you put into advancing our mission while delivering on the company's objectives. The dedication and resiliency are impressive. I wish you continued success.
謝謝你,Ivan,各位早安。我為我們在過去七年共同完成的成果感到自豪。我相信 Zimmer Biomet 擁有清晰的策略,且前方有重大的機會。我也想花一點時間感謝整個 Zimmer Biomet 團隊,感謝你們為推進我們的使命、同時達成公司的目標所付出的辛勤努力與投入。你們的投入與韌性令人印象深刻。祝各位持續成功。
Now turning to the results. Reviewing the first-quarter results, net sales were $2.087 billion, an increase of 9.3% on a reported basis, and 2.9%, excluding the impact of foreign currency and the Paragon 28 acquisition. Consolidated pricing was 40 basis points, negative in the quarter, in line with our expectations. Growth in the quarter benefited from opportunistic end-of-quarter purchases above historical levels, continued momentum from our recently launched products, as Ivan noted, and strong robotic sales.
接著看業績表現。回顧第一季結果,淨銷售額為 20.87 億美元,以報告基礎(reported basis)計年增 9.3%;若排除匯率與 Paragon 28 收購的影響,則成長 2.9%。合併定價在本季為負 40 個基點,符合我們的預期。本季成長受惠於季末高於歷史水準的機會性採購、如 Ivan 所提及我們近期上市產品的持續動能,以及強勁的機器人銷售。
Turning to our P&L. We reported GAAP diluted earnings per share of $1.22 compared to GAAP diluted earnings per share of $0.91 in the prior-year quarter. Higher revenue and lower restructuring costs, the previously mentioned tariff benefit and lower share count were partially offset by modestly higher taxes in the quarter due to geographic mix.
接著看損益表(P&L)。我們公布的 GAAP 稀釋後每股盈餘為 1.22 美元,對比去年同期 GAAP 稀釋後每股盈餘 0.91 美元。較高的營收與較低的重組成本、前述關稅利益以及較低的股數,部分被本季因地理組合而導致的稅負小幅上升所抵銷。
On an adjusted basis, we delivered diluted earnings per share of $2.09 compared to $1.81 in the prior year. This increase was driven by higher revenue, the aforementioned tariff benefit, and a lower share count, which were partially offset by increased commercial investments.
以調整後基礎計算,我們的稀釋後每股盈餘為 2.09 美元,對比去年同期的 1.81 美元。此增幅主要由較高的營收、前述關稅利益以及較低的股數所帶動,但部分被增加的商業投資所抵銷。
Adjusted gross margin was 73% and higher than the first quarter of 2025, driven by favorable mix and a benefit from tariffs. Notably, a portion of this tariff benefit included refunds that we had anticipated in the second half of the year. Adjusted operating margin was 27.3%. Adjusted net interest and non-operating expenses were $71 million, above the prior year driven by higher debt related to Paragon 28. Our adjusted effective tax rate was 18% and fully diluted shares outstanding were $195.8 million, down year over year due to $250 million of share repurchases in the first quarter.
調整後毛利率為 73%,高於 2025 年第一季,主要受惠於有利的產品組合以及關稅帶來的利益。值得注意的是,這部分關稅利益包含了我們原先預期在下半年取得的退款。調整後營業利益率為 27.3%。調整後淨利息與非營業費用為 7,100 萬美元,高於去年,主要因 Paragon 28 相關的較高負債所致。我們的調整後有效稅率為 18%,完全稀釋流通在外股數為 1.958 億股,因第一季進行 2.5 億美元的庫藏股回購而較去年同期下降。
Now turning to cash and liquidity. Another strong quarter of cash generation with operating cash flows of $359 million and free cash flow of $246 million. We ended the quarter with approximately $424 million in cash and cash equivalents. As Ivan had covered the rest-of-year outlook, I would like to close by again thanking the entire ZB team for their hard work and dedication.
接著看現金與流動性。本季現金創造再度強勁,營運現金流為 3.59 億美元,自由現金流為 2.46 億美元。本季結束時,我們持有約 4.24 億美元的現金及約當現金。由於 Ivan 已說明今年剩餘期間的展望,我最後想再次感謝整個 ZB 團隊的辛勤努力與投入。
And with that, I'll turn the call back over to David.
那麼,接下來我把電話交回給 David。
David DeMartino - Senior Vice President, Investor Relations
David DeMartino - Senior Vice President, Investor Relations
Thank you, Suky. Operator, let's open up for questions. (Operator Instructions) Operator, please go ahead.
謝謝你,Suky。接線員,請開放提問。(接線員指示)接線員,請開始。
Operator
Operator
Rick Wise, Stifel.
Rick Wise,Stifel。
Rick Wise - Analyst
Rick Wise - Analyst
Going to miss you, Suky. From my perspective, the year is off to a good start. You outperformed Ivan in the quarter, you beat sales, strong gross margin speeds, you beat [ETFs]. But just since I only have one question, but you didn't raise by overall by the beat. You left sales unchanged, EPS less than the EPS beat. I appreciate you keep talking about being more balanced and tempered as you think about guidance. But it's the start of the year. Is there -- are you seeing anything in the business or the market or competitively, or in your sales transition that prompts that conservatism beyond just again, your desire to stick with your tempered guidance?
會想念你,Suky。就我看來,今年開局不錯。本季你表現優於 Ivan,你的銷售超預期,毛利率提升速度強勁,你也超過了[ETFs]。但因為我只有一個問題:你們並沒有因為這次超預期而整體上調指引。你們讓銷售維持不變,EPS 的上調幅度也低於 EPS 的超預期。我理解你們一直在談,對指引的思考會更均衡、更克制。但現在是一年之初。請問——你們是否在業務、市場、競爭面,或是銷售轉型上,看到了任何促使你們更保守的因素?還是說,這只是你們再次希望維持克制指引的意願?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Rick, thanks for the questions. So as you highlighted, we had a very strong first quarter. And as I sit here looking at the next three quarters, the word that comes to mind is confident. I'm very confident that we're more in the right direction. We continue to see the sales force changes progressing as planned.
Rick,謝謝你的提問。如你所指出的,我們第一季表現非常強勁。而我坐在這裡看接下來三個季度,腦中浮現的詞是「有信心」。我非常有信心我們正朝著更正確的方向前進。我們也持續看到銷售團隊的變革按計畫推進。
We had some disruption in the quarter early in Q2, but everything is going in accordance to plan. We have a solid pipeline in technology. You saw the growth in technology, continue to see great momentum with new products. We've got a very robust list of new customer targeting strategies that are materializing. So from a revenue standpoint, I'm very confident that we are moving in the right direction.
我們在第二季初期確實有一些干擾,但一切都依照計畫進行。我們在科技(technology)方面有穩健的管線。你也看到科技的成長,我們持續看到新產品帶來很好的動能。我們也有一份非常強健的新客戶鎖定策略清單,正在逐步落地。因此從營收角度來看,我非常有信心我們正走在正確的方向上。
On EPS, we did raise. Maybe didn't raised by the entire bid. We're also investing in a variety of fronts, namely in the sales force and model changes. And we did raise free cash flow. So again, very solid first quarter, everything moving in the right direction.
在 EPS 方面,我們確實有上調,或許沒有把整個超預期幅度全部反映上去。我們也在多個面向進行投資,尤其是在銷售團隊與模式變更上。同時我們也上調了自由現金流。所以再次強調,第一季非常扎實,一切都在往正確方向前進。
So why are we not raising our guidance now? Because it's early in the year. This is a year of transition. We said so. We are making fairly substantial changes in a variety of fronts, go-to-market models here in the US, some changes in emerging markets, namely China. We're making investments in innovation at a ball pace. We're hiring people. We're making talent changes. So we feel, even though the first quarter was very strong, it's probably prudent to wait, let's call it, 90 days and then have the conversation again. But again, I'll leave you with one word, confident. Very confident that we move in the right direction. Thank you for the question.
那為什麼我們現在不上調指引?因為現在還在年初。這是一個轉型之年,我們也已經這麼說了。我們在多個面向進行相當重大的變革:在美國的 go-to-market 模式、在新興市場的一些變動,尤其是中國。我們正以很快的速度投資創新。我們在招募人才,也在進行人才調整。因此我們認為,即便第一季非常強勁,或許更審慎的做法是再等——就說 90 天——然後再來重新討論。不過我想留給你一個詞:有信心。我非常有信心我們正朝著正確方向前進。謝謝你的問題。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Congrats on a nice print here. And Suky, I wish you the best. Maybe one high level -- Ivan, and you mentioned US sales force transformation is on plan. Any -- you also made some interesting comments about -- you're seeing rapid increase in productivity in regions where you're seeing this transition. Any further details that you can share on other metrics that you're tracking perhaps, things like attrition rates? What percentage of sales force now dedicated or direct, if you will, in -- on the similar lane? And any macro impact that we need to think of outside of the sales force reorg? Anything from Middle East?
恭喜這次交出漂亮的成績。Suky,也祝你一切順利。先問一個較高層次的問題——Ivan,你提到美國銷售團隊轉型按計畫進行。你也提到一些有趣的觀察:在正在轉型的區域,你看到生產力快速提升。你能否再分享一些細節,例如你們在追蹤的其他指標,像是離職率?目前銷售團隊中有多少比例是專職(dedicated)或直屬(direct),如果這樣說的話——在同一條軌道上?另外,除了銷售團隊重組之外,是否有任何我們需要考量的總體環境影響?中東那邊有任何影響嗎?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Absolutely. So let me give you some of the key public metrics that we've been sharing. So at the beginning of the journey, early 2026, we mentioned that roughly 66%, so two-thirds of the US sales force, roughly 2,500 people, were 1,099. At the end of Q1, the number is already slightly below 60%. It's already roughly a 10% reduction on the number of 1,099s. And obviously, that implies that these 1,099s are now fully dedicated to Zimmer Biomet. So no longer they're doing Zimmer Biomet one or two other jobs. So a fairly significant decrease in the number of non-dedicated individuals.
當然可以。我先分享一些我們一直對外公開的關鍵指標。在這段旅程一開始,也就是 2026 年初,我們提到美國銷售團隊大約 66%,也就是三分之二、約 2,500 人,是 1,099。到第一季末,這個數字已經略低於 60%。也就是 1,099 的人數已經大約減少了 10%。而這也很明顯意味著,這些 1,099 現在已經完全專職服務 Zimmer Biomet,不再同時做 Zimmer Biomet 以及一兩個其他工作。因此,非專職人員的數量有相當顯著的下降。
We started the year with roughly 25% of the sales force being specialized. So one of every four reps carrying a dedicated sales back. Another number is approaching, if not exceeding 30%, [3-0 percent]. We [logged in], I believe and I spoke about this, Vijay, we [logged in] the top 6 independent distributors, accounting for roughly 40% of sales. They're in extension of no less than seven years with Zimmer Biomet. So that was a fairly significant risk that we retired.
我們在年初時,約有 25% 的銷售團隊是專科化(specialized)的,也就是每四位業務中就有一位背負專職的銷售包(dedicated sales bag)。現在這個數字已接近、甚至可能超過 30%([3-0 percent])。另外,我們也——我相信我也跟你提過,Vijay——我們已經[logged in]前 6 大獨立經銷商,他們合計約占 40% 的銷售額,並且與 Zimmer Biomet 簽有至少 7 年的延長合約。這等於是我們消除了相當重大的風險。
Relative to turnover rates, we had a target of no more than 12% turnover given the changes, and our turnover rate is in the single-digit range. So again, early in the year, only 90 days behind, but everything is progressing in accordance to plan. To the point that we're thinking that perhaps we could go a bit faster as we get into Q2, Q3, and the rest of 2026, with the commitment is still being we're going to close the entire transformation by the end of 2027.
至於離職率(turnover rates),考量到這些變革,我們的目標是離職率不高於 12%,而目前離職率落在個位數百分比。再次強調,現在還在年初,只過了 90 天,但一切都按計畫推進。甚至我們也在思考,進入第二季、第三季以及 2026 年剩餘時間後,或許可以再加快一些速度;但我們的承諾仍然是:在 2027 年底前完成整個轉型。
I believe you had a second question or part two of the question. Anything else, any follow-ups there?
我記得你還有第二個問題或第二部分。還有其他補充或追問嗎?
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Just on the macro piece, Middle East, any impact?
就總體環境那一塊,中東有任何影響嗎?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Okay. Middle East. From a macro standpoint, obviously, like everybody else, we continue to monitor what's happening in the Middle East. Today, we have seen no material supply disruptions, a minor freight cost increase in the quarter that we're able to absorb. From a supply standpoint, most of our key products are dual source, if not three sources. We got at least one year of poly. So this is not something that we're concerned about. So we're not seeing any distribution challenges there. So again, so far, life is good.
好的,中東。從總體環境角度來看,顯然我們跟其他人一樣,持續關注中東正在發生的事情。截至目前,我們沒有看到任何重大的供應中斷;本季運費成本有小幅上升,但我們可以吸收。從供應角度,我們大多數關鍵產品都有雙來源,甚至三來源。我們也至少有一年的 poly(原料)庫存。因此這不是我們擔心的事情。我們也沒有看到那邊有任何配送上的挑戰。所以再次強調,到目前為止,一切都很好。
And then from a sales-impact standpoint, we didn't see any impact in the first quarter. So that's on the Middle East. And then you got a variety of other macro or deals that we're monitoring, but nothing that it was impactful in the quarter, and nothing that we see has been impactful in the second quarter and beyond. Thank you for the question, Vijay.
另外從銷售影響的角度,我們在第一季沒有看到任何影響。以上是中東的部分。至於其他各種我們正在監控的總體或交易面因素,本季沒有任何造成影響的事項,我們也沒有看到第二季及之後會有影響。謝謝你的問題,Vijay。
Operator
Operator
Matthew Blackman, TD Cowen.
Matthew Blackman,TD Cowen。
Mathew Blackman - Equity Analyst
Mathew Blackman - Equity Analyst
Ivan, Vijay actually asked this, I think, in those list of questions, but I'm not sure that you touched on it. You did talk to seeing increasing productivity in some of the geographies where you're doing the sales force work. I was just hoping maybe you could expand a little bit on that, just maybe in general, talk to some -- to the extent that you're seeing any green shoots, let's call it, from the work that you've done maybe in the latter part of '25 or maybe even early here in 2026. That's worth calling out that gives us confidence in the lift that you still have ahead of us -- ahead of you.
Ivan,Vijay 其實在那串問題裡也問到了這點,但我不確定你是否有觸及。你確實談到在一些正在進行銷售團隊調整的地區,你看到生產力提升。我希望你能再多展開一點,從較一般性的角度談談——在你們於 25 年下半年、或甚至 2026 年初所做的工作中,是否已經看到一些「綠芽」(green shoots)?有沒有什麼值得特別點出的訊號,能讓我們對你們後續仍有的提升空間更有信心——也就是你們前方仍可實現的提升。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
I appreciate the question, Matt. So we probably could spend an hour going through data points. As you can imagine, given the magnitude of the project, we're tracking all gaps of KPIs, but I'll give you maybe three or four reasons to believe. In the territories that we did switch from non-dedicated to dedicated. So again, a 10% reduction, we've seen fairly dramatic improvements in productivity.
謝謝你的問題,Matt。我們大概可以花一個小時逐一檢視各種數據點。你可以想像,考量到這個專案的規模,我們在追蹤各式各樣的 KPI,但我先給你三到四個值得相信的理由。在我們把區域從非專職轉為專職的那些地盤——也就是 1,099 人數減少約 10% 的地方——我們看到生產力有相當顯著的改善。
Nationwide or average [rate was] around 7 cases our lead competitor is in the 16, 17 cases per week run in the territories where we made the switches already are in double-digit ranges for the number of cases. So that's pretty encouraging to see very quickly that improvement, no surprise.
全國或平均水準大約是每週 7 台(cases),而我們的主要競爭對手是每週 16、17 台;在我們已經完成切換的那些地盤,每週台數已經來到雙位數。能在很短時間內看到這樣的改善相當令人鼓舞,也不令人意外。
When you go from spending two, three days, are we doing cases to five days, you can imagine the product that is going to increase. Along with productivity increases, we've seen sales improvement in those dedicated structures. Our average extremities shoulder number for the quarter was strong. That is directly correlated to the number of shoulder specialists that we have added, both in an inpatient HOPD structure as well as in ASCs, and we continue to see great momentum in shoulders.
當你從每週花兩三天在做手術台(cases),變成五天都在做,你可以想像產出會如何提升。除了生產力提升之外,我們也看到這些專職架構下的銷售有所改善。我們本季在四肢(extremities)與肩關節(shoulder)的平均表現很強,這與我們新增的肩關節專科人員數量直接相關,這些人員同時涵蓋住院的 HOPD 架構以及 ASC。我們也持續看到肩關節業務的強勁動能。
So productivity is improving number of cases. Sales is improving in those territories. The lower turnover rates that I was -- according to Vijay, is mostly coming from some of these story changes, higher engagement once we become fully part of the company. So again, plenty of reasons to be in that we're in the right direction.
所以,生產力在提升(手術台數增加),這些地盤的銷售也在改善。我先前跟 Vijay 提到的較低離職率,主要也來自其中一些架構調整:當我們成為公司的一部分、完全整合後,員工投入度更高。因此,再次強調,有很多理由讓我們相信我們正朝著正確方向前進。
Operator
Operator
Robbie Marcus, JPMorgan.
Robbie Marcus,摩根大通。
Robert Marcus - Analyst
Robert Marcus - Analyst
Suky, I'll add, I guess, my sadness and congratulations. You'll be missed. I wanted to follow up, Ivan, maybe on a couple of things you mentioned. And it really comes down to what is and what isn't maybe onetime in the quarter? It seems like there were some product discontinuations in these, maybe a little bit of end-of-quarter purchasing and then perhaps maybe some benefit in gross margin. Wondering if you could size any of those? Any other potentially one-time items in the quarter and how to think about that resolving over the rest of the year?
Suky,我想補充一下,我既感到難過也要向你道賀。你會被想念的。我想跟進一下,Ivan,針對你提到的幾件事。核心其實在於:本季哪些是一次性因素、哪些不是一次性?看起來這裡面有一些產品停產,可能還有一點季末採購,然後或許毛利率也有一些受益。想請你能否量化一下這些影響?本季還有沒有其他可能的一次性項目?以及該如何看待這些因素在今年剩餘期間的消退/回歸常態?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Absolutely. Thank you, Robbie. So I'll touch on US needs and what happened in the quarter, and then maybe Suky, you can comment on gross margins and how durable they are.
當然。謝謝你,Robbie。我會先談談美國膝關節業務的需求以及本季發生了什麼,然後也許 Suky 你可以評論一下毛利率以及其可持續性。
So look, it was not the greatest quarter for US Knees, but it was definitely in alignment to our expectations. We knew we were going to be going through some of these changes related to the go-to-market transformation, and we accounted for those. So I would say the single largest reason why the USD number was no higher than the 2.2% is some of the changes that we made in the US organization.
你看,美國膝關節這一季並不是最好的季度,但確實符合我們的預期。我們知道在推進部分與市場進入(go-to-market)轉型相關的變更時,會經歷一些調整,我們也已將其納入考量。所以我會說,美元口徑增長沒有高於 2.2% 的最大單一原因,是我們在美國組織上做出的一些變動。
We lost two accounts in the quarter, fairly large. We believe going to be able to recoup some of the business, but we'll see as we get into the rest of the year. There was a Kaiser strike in the West Coast where we had the highest share in Knees. So while that was disrupted for everybody, it was more disruptive for us.
我們在本季流失了兩個客戶,規模相當大。我們相信能夠收回部分業務,但還要看今年剩餘時間的進展。西岸的 Kaiser 發生罷工,而我們在膝關節領域在那裡的市占最高。因此雖然對所有人都有影響,但對我們的干擾更大。
In my prepared remarks, Robbie, mentioned how we are moving from legacy brands, namely NexGen and Vanguard to making the transferring to a one new franchise, that being Persona. And as we went through that, we saw some disruption. So I will tell you, probably mostly in line, except a couple of the accounts that we lost -- and that's the [both of it]. We got to do better, and we expect to do better than growing 2.2% in US Knees.
在我事先準備的發言中,Robbie,我提到我們正從傳統品牌(主要是 NexGen 與 Vanguard)轉移,並整合到一個新的產品平台,也就是 Persona。在推進這個過程中,我們確實看到一些擾動。所以我會告訴你,整體大致符合預期,除了我們流失的那幾個客戶——那就是(兩者的影響)。我們必須做得更好,也預期美國膝關節的成長會優於 2.2%。
Relative to quarter-end deals, all the staff, those are in line with what we typically do. It was not a significant one-time event. We do strategic purchases. We try to convert ASCs. There is demand in the market for bundled deals, we include technology, implants, and whatnot, and we're going to continue to do those.
至於季末交易、所有這些事項,都與我們通常的做法一致,並不是重大的單次事件。我們會做策略性採購。我們嘗試轉換 ASC(門診手術中心)。市場對打包方案有需求,我們會把技術、植入物等納入其中,而且我們會持續這麼做。
Suky, do you want to comment on gross margin?
Suky,你要不要評論一下毛利率?
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Robbie, on gross margin, we saw a very strong quarter, largely driven by the invalidation of the IEEPA tariffs, which contributed about $0.20 to results in the quarter. We were beyond that a little bit better on underlying performance as well. The way you should think about the gross margin line is of that $0.20 that we benefited in Q1. We had originally assumed about half of that would be credited in the second half. So that was a bit of a pull forward, and so the remainder of that $0.20 drops $0.10 to the bottom line, and is largely the driver of the beat or the raise, I should say, on earnings per share.
Robbie,關於毛利率,我們本季表現非常強勁,主要由 IEEPA 關稅被判定無效所帶動,這在本季對結果貢獻約 0.20 美元。除此之外,我們在基本面表現上也略優於預期。你應該這樣看毛利率這一行:Q1 我們受益的這 0.20 美元中,我們原先假設大約一半會在下半年入帳。因此這次有一部分是提前反映(pull forward)。所以這 0.20 美元中剩餘的部分,約有 0.10 美元會落到淨利(bottom line),也基本上是每股盈餘超預期、或者我該說上調的主要驅動因素。
As you think about gross margin for the full year, we still expect it to be down modestly versus prior year at around 71%, give or take. And the way you should think about the cadence is that it's going to be roughly consistent for the remainder of the quarters. So again, underlying performance on gross margin is as expected. The biggest driver in Q1 was the invalidation of those tariffs.
至於全年毛利率,我們仍預期會較去年小幅下降,約在 71% 左右,上下些許浮動。節奏方面,你可以預期接下來各季大致會維持一致。因此,毛利率的基本面表現符合預期;Q1 最大的驅動因素是那些關稅被判定無效。
Operator
Operator
Travis Steed, Bank of America.
Travis Steed,美國銀行。
Travis Steed - Analyst
Travis Steed - Analyst
Just to follow up a little bit on Robbie's question. I guess looking at the US Knees specifically, comps do get 400 basis points tougher in the back half. And so just how do we get confidence that in the the back-half acceleration in US Knees? And I don't know if I heard correctly, was there -- did you say in the earlier question, you saw some disruption early in Q2. I don't know if that was an early Q1 misspeak or maybe I missed it wrong?
我想稍微跟進一下 Robbie 的問題。我想特別看美國膝關節,後半年比較基期會變得困難 400 個基點。所以,我們要如何對美國膝關節在後半年的加速更有信心?另外我不確定我是否聽對了——你在前一個問題時是不是說,你在第二季初看到一些擾動?我不知道那是你把第一季說成第二季,還是我聽漏了?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
No, no. The disruption was on Q1, Travis. So when you look at the changes we made in the first quarter, I noted a reduction on non-dedicated representatives. There was some disruption. We did lose two fairly large accounts in the quarter. So no, I did not comment on disruption on the second quarter.
沒有沒有。擾動是在第一季,Travis。所以當你看我們在第一季做的變更時,我提到我們減少了非專職(non-dedicated)的業務代表。確實有一些擾動。我們本季也流失了兩個相當大的客戶。所以不,我沒有評論第二季的擾動。
Your main question, what gives us confidence that we're going to accelerate our Knee growth in the second half is the ramp-up of our new products, is the fact that we continue to place and sell a lot of technology, 30% growth in technology in the first quarter, all in with the rest of surgery. Bond cement is 12%, but the actual technology growth in the first quarter, and that's TMINI, that's ROSA, that's ROSA optimized, is 30%. So once you start growing technology at those rates, obviously, implants fall at some point.
你的主要問題是:是什麼讓我們有信心在下半年膝關節成長會加速?答案是新產品的放量(ramp-up),以及我們持續大量布建並銷售技術產品——第一季技術成長 30%,與其他手術相關的整體一起看。骨水泥(Bond cement)是 12%,但第一季真正的技術成長——包括 TMINI、ROSA、ROSA optimized——是 30%。當你以那樣的速度推動技術成長時,顯然植入物在某個時間點也會跟上。
So the account conversions that we've seen in the technology sales, the changes we're making from a go-to-market standpoint, new product acceleration gives us confidence that the numbers should increase. Thank you, Travis.
因此,我們在技術銷售上看到的客戶轉換、我們在 go-to-market 方面所做的調整,以及新產品加速,讓我們有信心數字應該會上升。謝謝你,Travis。
Operator
Operator
Chris Pasquale, Nephron.
Chris Pasquale,Nephron。
Chris Pasquale - Analyst
Chris Pasquale - Analyst
It didn't come up in your prepared remarks, but one of your competitors have been dealing with an issue that impacted their ability to serve customers for a few weeks at the end of the quarter doesn't appear to me at first glance like you benefited much from that dynamic. But could you just talk about what you've seen in the market and whether you think that has any implications for your business, either here in the first quarter or what you're expecting in 2Q.
你在事先準備的發言中沒有提到,但你們的一位競爭對手一直在處理一個問題,導致他們在本季末有幾週無法服務客戶。乍看之下,我覺得你們似乎沒有從這個情況中獲得太多好處。但你能否談談你們在市場上看到的情況,以及你認為這對你們的業務是否有任何影響——不論是在第一季,或是你們對第二季的預期?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Thank you, Chris. First things first, it's very unfortunate that companies go through those dynamics. So I'll start with that. No, we did not see any material impact. So we do not see the fact that we had a competitor going through such dynamic impacting our business in a meaningful way.
謝謝你,Chris。首先,企業遇到那樣的情況是非常不幸的,我先這麼說。不過,我們沒有看到任何實質性的影響。因此,我們不認為競爭對手經歷那樣的狀況,對我們的業務造成有意義的影響。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛。
David Roman - Analyst
David Roman - Analyst
Maybe we could unpack a little bit some of the trends outside the United States. I think this is the first quarter in quite some time that OUS growth has trailed the US and likely trailed where end markets look to be performing. So could you maybe help us think through some of the factors influencing those geographies to the extent to which there might have been any type of intermittent disruption versus what might be a change in the trajectory of that franchise?
也許我們可以稍微拆解一下美國以外地區的一些趨勢。我認為這是相當長一段時間以來,首次出現 OUS(美國以外)成長落後於美國,且可能也落後於終端市場表現的季度。所以你能否幫我們梳理一下影響這些地區的因素?以及其中有多少可能是間歇性的擾動,或有多少可能代表該產品線成長軌跡的改變?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Thank you, [I find] you, David. So a couple of things. Number one, the comps in the first half for International are the -- are more difficult than the second half. So that's one part, and I would like to talk what comes, but it is definitely an element here.
謝謝你,David。幾點說明。第一,國際市場在上半年的比較基期——比下半年更具挑戰。這是一部分原因,我也想談談接下來的走勢,但這確實是其中一個因素。
Secondly, we've made, as we announced at the end of 2025 and as we said in 2026 early in the year, we made and we're making some distributor changes in geographies such as Emerging Markets, Middle East, and Europe, and China primarily, where we have gone from a large network of distributors to having one, if not true partners. And that's obviously brought some disruption.
第二,我們已經做了、也正在做一些經銷商調整——正如我們在 2025 年底宣布、以及 2026 年初所說的——在新興市場、中東、歐洲,以及主要在中國等地區,我們從龐大的經銷商網絡,轉為只保留一家(或少數)真正的合作夥伴。這顯然帶來了一些擾動。
And then thirdly, there were a couple of one-time events that have been orders in certain geographies internationally that didn't come or wait. But all of that said, the expectation is that we're going to be growing International mid-single digit in the second half of 2026.
第三,國際某些地區還有幾個一次性事件,原本應該下單的訂單沒有進來或被延後。但即便如此,我們的預期仍是:2026 年下半年國際業務將以中個位數成長。
Thanks for the question, David.
謝謝你的問題,David。
Operator
Operator
Larry Biegelsen, Wells Fargo.
Larry Biegelsen,富國銀行。
Lawrence Biegelsen - Analyst
Lawrence Biegelsen - Analyst
I guess for my one question, Ivan, I'd love to hear about the rollout of Monogram. I know it's early, but it's an important product for you. So once you launch the semi-autonomous system with Persona early next year, how should we think about the pace of the rollout? Will there be a limited launch initially at select centers and how that might impact ROSA? Just help us think about that, please.
我想就一個問題,Ivan,我很想聽你談談 Monogram 的推廣進度。我知道現在還早,但這對你們是個重要產品。所以當你們在明年初推出搭配 Persona 的半自主系統後,我們應該如何看待推廣速度?一開始會不會在特定中心做有限度上市?以及這可能如何影響 ROSA?請幫我們梳理一下。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Larry, I love the fact that you always got a technology-related questions about the future of the company. So thank you for that. Very excited about Monogram. As I mentioned in my prepared remarks, we completed the clinical trial. So we are deeply focused now on the preparation of the 510(k) submission. And we continue to anticipate that we're going to be in a position to launch this new-to-the-world technology in early 2027.
Larry,我很喜歡你總是問與技術相關、關於公司未來的問題,謝謝你。我們對 Monogram 非常興奮。如我在事先準備的發言中提到的,我們已完成臨床試驗。現在我們高度聚焦在 510(k) 申請文件的準備上。我們仍預期能在 2027 年初推出這項全球首創(new-to-the-world)的技術。
What should we expect of Monogram? If what we've proven is right, the fees remain there going to be launching the most efficient readout there in what we can do cases under 4 minutes procedure times. We believe that it's going to have the highest amount of safety given the enhanced surgical boundaries. We believe that it's going to really democratize orthopedic cases from a technology standpoint, very consistent when it comes to a procedure is very reproducible. The learning curve is very short. So it is easy to use.
我們對 Monogram 應該有什麼期待?如果我們已經證明的方向是正確的,費用會維持在那裡;我們將在我們能做到的情境下推出最有效率的讀取結果,手術時間可控制在 4 分鐘以內。我們相信,憑藉強化的手術邊界,它將具備最高等級的安全性。我們相信,從技術角度來看,它將真正讓骨科手術更普及;在手術一致性方面非常穩定、可高度重現。學習曲線非常短,所以很容易使用。
And then again, the level of accuracy we've seen with the robot is like nothing that I've seen in my many years dealing with technology. So we believe we got a bulk platform that can get scale up fairly rapidly. And to that point, we are going to invest to make sure that's the case. So we are hiring north of 200 sales reps behind the launch of Monogram in addition to the many reps that already got in the field.
再者,我們在機器人上看到的精準度,是我多年接觸科技以來前所未見的。因此我們相信,我們擁有一個可以相當快速擴大規模的核心平台。也正因如此,我們將投入資源以確保能做到這一點。所以,除了目前已在市場上的眾多業務代表之外,我們也將在 Monogram 上市背後再增聘超過 200 位業務代表。
We are investing heavily on clinical evidence. We recently announced that we hired Dr. Jonathan Vigdorchik, who happens to be one of the world's global key opinion leaders when it comes to technology, some of who's actually been an entrepreneur as well. We're also investing in rethinking, or rather thinking, not just the clinical strategy, but also the economic strategy.
我們正大力投資臨床證據。我們最近宣布聘請 Jonathan Vigdorchik 醫師,他剛好是全球在科技領域的關鍵意見領袖之一,而且其中也有人本身是創業家。我們也在投資重新思考——或者說不只是思考——不僅是臨床策略,也包括經濟策略。
So I can spend an hour talking about it, but I will say this is going to be a very bold launch, one that we're prepared already as we speak. What's going to happen with ROSA? We are committed to having a suite of technology solutions. So ROSA OptimiZe was recently launched. One of the reasons why technology is growing 30%, we're going to keep that. It is the number one robot outside of the US where CT scan is not CT scanning, it's not the preference.
所以我可以花一個小時談這件事,但我想說的是:這將會是一個非常大膽的上市,我們此刻就已經在做準備。那 ROSA 會怎麼樣?我們承諾要提供一整套的技術解決方案。因此 ROSA OptimiZe 最近已經推出。技術業務能成長 30% 的原因之一就是它,我們會持續推進。它是在美國以外、在不偏好 CT 掃描的市場中排名第一的機器人。
We love what we're seeing with our partnership with THINK Surgical and TMINI. So we strongly believe that the combination of Monogram, plus ROSA, plus TMINI. It's going to give us a competitive advantage. Very excited about Monogram. Thanks for the question.
我們很喜歡與 THINK Surgical 以及 TMINI 的合作所呈現的成果。因此我們堅信,Monogram 加上 ROSA 再加上 TMINI 的組合,將帶給我們競爭優勢。對 Monogram 非常興奮。謝謝你的提問。
Operator
Operator
Matt Taylor, Jefferies.
Jefferies 的 Matt Taylor。
Matthew Taylor - Equity Analyst
Matthew Taylor - Equity Analyst
I actually wanted to ask a [final] question about the tariff impact you saw the benefit here in Q1. I guess what are you assuming for the rest of the year with regards to [EBIT] tariffs or tariffs in general? And what do you think could happen with the 232 investigations? Just asking a curiosity more than anything else.
我其實想問一個關於關稅影響的【最後】問題:你們在第一季看到這裡有一些好處。我想問的是,對於今年剩下的時間,在【EBIT】關稅或一般關稅方面,你們的假設是什麼?另外,你們認為 232 調查可能會發生什麼事?更多是出於好奇而問。
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Yes. Matt, good to talk to you. So we are assuming that the 122 tariffs remain intact for -- into the second half of the year. We are assuming that the IEEPA remain invalidated. And therefore, we took the benefit of that $0.20 in the first quarter, as I mentioned. And moving forward on the 232, I think it's still evolving and dynamic and no material updates at this point, but the overall situation remains fluid, and we'll keep you posted as things unfold.
是的。Matt,很高興和你交流。我們的假設是:122 關稅在今年下半年仍會維持不變。我們假設 IEEPA 仍然維持被判定無效。因此,如我提到的,我們在第一季反映了每股 0.20 美元的利益。至於 232,我認為仍在演變且具動態性,目前沒有重大更新;但整體情勢仍然多變,我們會在事態發展時持續向各位更新。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
I'll just add Matt, quickly. On the 232, the validation we're getting from our IEEPA sources is that it's not going to impact those companies that operate under the Nairobi protocol. So we're feeling pretty confident that we've got a pathway to mitigate that. Thank you.
Matt,我再快速補充一下。關於 232,我們從 IEEPA 的消息來源得到的確認是:它不會影響那些在 Nairobi protocol(奈洛比協議)下運作的公司。因此我們相當有信心有一條路徑可以加以緩解。謝謝。
Operator
Operator
Richard Newitter, Truist Securities.
Truist Securities 的 Richard Newitter。
Richard Newitter - Analyst
Richard Newitter - Analyst
One of the innovations that feels most innovative for you guys that's exclusively in your hands. It's the Canary Smart Implant that's embedded in Persona IQ. But just noticed it doesn't get a ton of airtime even on this call. And I know you had some positive clinical trial updates at AAOS for this technology. It seems like there's potential to generate real savings to the system here, better patient management post surgery. I know in the most recent CMS in-patient rule proposal, the CCJR is extending, some of those initiatives that would seem to lend themselves in favor of a technology like this.
你們手上有一項我覺得最具創新性的創新,而且是你們獨有的:嵌入在 Persona IQ 裡的 Canary 智慧植入物。但我注意到,即使在這通電話上,它也沒有被提到太多。我知道你們在 AAOS 上也針對這項技術發布了一些正向的臨床試驗更新。看起來它有潛力為整個醫療體系帶來實質節省,並在術後提供更好的病患管理。我也知道在最新的 CMS 住院規則提案中,CCJR 正在延長;其中一些倡議似乎也更有利於這類技術。
I'd just love to hear where you are on this particular product subsegment? Why we're not hearing about it more? How and if this can be leveraged as a more meaningful differentiator moving '26 into '27?
我很想聽聽你們在這個特定產品子領域目前的進展?為什麼我們沒有聽到更多?以及這項產品如何、以及是否能在 2026 年走向 2027 年時,被運用成更有意義的差異化因素?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
A lot of the question, Richard. Thank you. Look, early on, probably, we talked too much about Persona IQ without having the data. Now we're taking a different approach. We're going to get all the data. We're going to get everything validated, and they want to talk about it. I will tell you, overall, everything is tracking in accordance with expectations. As you mentioned, we did publish some very robust data on what Persona IQ brings in terms of lowering cost, improving outcomes, et cetera, et cetera. So that was published, I think it was four to six weeks ago.
Richard,這個問題涵蓋很多面向,謝謝。坦白說,早期我們可能在沒有數據的情況下,對 Persona IQ 談得太多。現在我們採取不同做法:我們要把所有數據都拿到手、把一切都完成驗證,然後再來談。我可以告訴你,整體而言,一切都依照預期在推進。如你所提到的,我們確實發布了一些非常扎實的數據,說明 Persona IQ 在降低成本、改善結果等方面所帶來的價值。我想那是在大約四到六週前發布的。
I've seen with some of the changes around IPPS and the CJR expansion. This is the kind of product that can make a robust impact. There is an increase on DRGs or expenditures, as you say, with DRGs 469 and 470 for those companies that perform better. So now we will be in possession of the implant that can, in an objective way, track whether our implant is performing better.
我看到隨著 IPPS 與 CJR 擴大等變化,這正是能產生強勁影響的產品類型。對於表現更好的機構而言,DRG(或你說的支出)會有所增加,特別是 DRGs 469 與 470。現在我們將擁有一種植入物,能以客觀方式追蹤我們的植入物是否表現更好。
So companies that have connected data before, during, and after the procedure. Companies that can being objective data around outcomes, promo whatnot, and they can validate that can reduce the cost of care, I believe they're going to be meaningfully rewarded. So we continue to invest in a variety of fronts to make sure that we are the company that can validate all of the above. So committed to the space, the technology, and we like what we see.
因此,那些能在手術前、手術中與手術後都連結資料的公司;那些能提供關於結果、PROMs(病患回報結果量表)等客觀數據,並能驗證其可降低照護成本的公司,我相信將會獲得實質性的回饋。因此我們持續在多個面向投資,以確保我們就是能驗證上述所有事項的公司。我們對這個領域與這項技術保持承諾,也很喜歡目前看到的進展。
Operator
Operator
Caitlin Roberts, Canaccord Genuity.
Canaccord Genuity 的 Caitlin Roberts。
Caitlin Cronin - Equity Analyst
Caitlin Cronin - Equity Analyst
Just to touch on ROSA Shoulder. Any updated color on the launch and when will move to a broader launch?
想請教一下 ROSA Shoulder。關於上市進度有沒有更新?以及什麼時候會推進到更廣泛的上市?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Caitlin, thanks for the question. We are now fully on the full-market release. I was actually done in Florida, where we've been demoing the technology. The feedback continues to be very strong. It is surgeon center. So we're not launching a technology that only certain surgeons can use. So if you are an anatomic or reversed type of surgeon case technique, you can use ROSA Shoulder for both types of surgery.
Caitlin,謝謝你的提問。我們現在已經全面進入全市場釋出(full-market release)。我其實剛在佛羅里達完成展示這項技術的活動。回饋持續非常強勁。這是以外科醫師為中心的設計,所以我們不是在推出只有特定外科醫師才能使用的技術。無論你是做解剖型(anatomic)或反置型(reverse)手術技術的外科醫師,你都可以用 ROSA Shoulder 來進行這兩種手術。
We are getting really solid data around the accuracy of the platform. So we can robotically do surgeries that impact the glenoid as well as the humoral, so we can do both the glenoid [ream and] humeral resection. It is extremely efficient. We already are actively working on version 2 that's even more efficient than the first generation of ROSA Shoulder and it is fully integrated to the rest of the ROSA ecosystem.
我們也取得了非常扎實的平台精準度數據。我們可以用機器人方式進行會影響盂窩(glenoid)以及肱骨(humeral)的手術,因此我們可以同時處理盂窩【擴刮/磨削(ream)】與肱骨截骨(humeral resection)。效率極高。我們也已在積極開發第 2 版,其效率甚至比第一代 ROSA Shoulder 更高,並且已完整整合到 ROSA 生態系的其他部分。
So again, another example going back to the question that Rich had of collecting data before doing after surgery with ROSA Shoulder and being able to engage in proms, conversations, outcomes, and whatnot. So again, we move from limited market release to full market release, and we're going to scale up the number of units that we're going to be deploying in the US and other markets. Thank you, Caitlin.
所以再一次,回到 Rich 的問題,這是另一個例子:用 ROSA Shoulder 在術前、術中、術後收集資料,並能就 PROMs、溝通、結果等進行互動。因此,我們已從有限市場釋出(limited market release)轉為全市場釋出,並將擴大在美國及其他市場部署的設備數量。謝謝你,Caitlin。
Operator
Operator
Matt Miksic, Barclays.
Barclays 的 Matt Miksic。
Matthew Miksic - Analyst
Matthew Miksic - Analyst
Follow-up on Paragon. You mentioned some acceleration there. If you could talk about what's driving that and whether you expect to maybe exit the year on double digits? And how we should think about the time line for another potentially paradigm like strategic investments?
追問 Paragon。你提到那邊有些加速成長。能否談談是什麼在驅動?以及你們是否預期年底可能以雙位數成長作結?另外,我們應該如何看待下一筆可能類似 Paragon 的策略性投資的時間表?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Thanks, Pat. So we actually -- the first quarter almost a double digit when it comes to Paragon 28. And early in the second quarter, we are in the teens. So the growth is accelerating. We also saw a 200-basis-point sequential increase from Q4 of 2025 to Q1.
謝謝,Pat。我們其實——第一季在 Paragon 28 幾乎達到雙位數成長。而在第二季初期,我們已經來到十幾%的成長,所以成長正在加速。我們也看到從 2025 年第四季到第一季,序列成長提升了 200 個基點。
And to answer your question succeedingly, what's driving this is focus. We live in Albert and the Timalon. They're getting robust investments behind the platform. The launching products at a rapid pace, the hiring reps in a variety of fronts. So focus is what's driving the growth here. And we expect to exceed 2026 strongly in the double-digit growth rates.
再更直接回答你的問題:驅動因素是聚焦。我們在 Albert 和 Timalon(音譯)上投入了強而有力的資源支持這個平台;以很快的節奏推出產品;在多個面向增聘業務代表。所以,聚焦是推動這裡成長的關鍵。我們預期 2026 年將明顯維持在雙位數成長率之上。
In terms so when are we ready to do the next deal. Look, we've got a lot going on here. We are changing the go-to-market model here in the US, integrating Paragon, about to launch Monogram, which is going to be very disruptive and it's required a lot of focus. And then we've got another deal called OrthoGrid, also doing really well that we're integrating. So we're going to pause. We're going to continue to do buybacks. And at the right time, we'll execute on a deal similar to Paragon, which I think is prone to be very solid for Zimmer Biomet.
至於什麼時候準備好做下一筆交易。坦白說,我們目前手上有很多事情在進行:我們正在改變美國的 go-to-market(上市/商業化)模式、整合 Paragon、即將推出 Monogram——這會非常具顛覆性,也需要大量專注。此外我們還有另一筆交易 OrthoGrid,目前表現也很好,我們正在整合中。所以我們會先暫停。我們會持續進行庫藏股回購。而在適當的時機,我們會執行一筆類似 Paragon 的交易;我認為那對 Zimmer Biomet 會非常扎實。
Thanks for the question, Matt.
謝謝你的提問,Matt。
Operator
Operator
Steve Lichtman, William Blair.
Steve Lichtman,William Blair。
Steven Lichtman - Equity Analyst
Steven Lichtman - Equity Analyst
Suky, all the best to you. Ivan, where do you think we are at on underlying Hip and Knee market growth? Are there any incremental headwinds to market growth in the US that you're seeing on elective procedures or willingness of your hospital customers to purchase bigger ticket items like ROSA?
Suky,祝你一切順利。Ivan,你認為髖關節與膝關節的基礎市場成長目前處於什麼狀態?你是否看到美國在市場成長方面有任何新增的逆風,例如選擇性手術量或你們的醫院客戶在購買像 ROSA 這類高單價項目上的意願?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
We continue to track the market growth rates and it's very solid. We pick the overall recon market to be growing north of 4%, north of 4.5%. So obviously, we got to do better in Knees. We are where we need to be, but we're going to accelerate in Hips. We've not seen any material impacts. I get the question around what's happening with Medicaid, ACA, and whatnot. We track all [casts of] data. First of all, Medicaid is low-single digit for us. So said differently, I think it's about 1% of our revenue comes from Medicaid, less than that. And then in terms of ACA, is less than 1%, 2% of our cases.
我們持續追蹤市場成長率,表現非常穩健。我們判斷整體重建(recon)市場的成長在 4% 以上、4.5% 以上。所以很明顯,我們在膝關節業務上必須做得更好。我們目前在該做的方向上,但我們會在髖關節業務上加速。我們沒有看到任何實質性的影響。我理解你問到 Medicaid、ACA 等相關情況。我們追蹤所有(各類)數據。首先,Medicaid 對我們而言占比是低個位數。換句話說,我認為大約 1% 的營收來自 Medicaid,甚至更低。至於 ACA,則不到 1%~2% 的病例量。
We track the top 10 accounts in the US to 10 accounts being hospitals like Mayo, Cleveland, HSSC in New York, and other. We continue to see waiting lease being fairly long. So I would say the market is 4%, 4.5% durable. Pricing dynamics continue to be where they need to be.
我們追蹤美國前 10 大客戶,這 10 個客戶是像 Mayo、Cleveland、紐約的 HSSC 等醫院,以及其他機構。我們持續看到等待名單仍然相當長。因此我會說,市場 4%~4.5% 的成長具有持續性。定價動態也仍在我們需要的水準。
So we had a quarter of 40 basis points of price erosion overall, in line with our expectations. So we don't see anything from a market perspective that we're concerned about. Thank you.
因此我們這一季整體價格侵蝕為 40 個基點,符合我們的預期。所以從市場角度來看,我們沒有看到任何讓我們擔憂的事情。謝謝。
Operator
Operator
Jeff Johnson, Baird.
Jeff Johnson,Baird。
Jeffrey Johnson - Senior Research Analyst
Jeffrey Johnson - Senior Research Analyst
Suky, best of luck. Ivan, maybe on the sales transition. I know we covered a lot of this last quarter, but I just want to make sure I'm understanding a couple of things we've heard in some conversations. I think some of your reps that were not 100% dedicated, you're truing up and giving them guarantees this year. That extra stub that you may be guaranteeing some of those reps. Are you excluding those costs from non-GAAP EPS and margins, just I think about how to set my model up for next year or this year and next year?
Suky,祝你一切順利。Ivan,想請教銷售轉型的部分。我知道我們上季已談了很多,但我想確認我是否理解了我們在一些對話中聽到的幾點。我認為你們有些業務代表並非 100% 專職,你們今年在做調整並提供保底(guarantees)。你們可能對其中一些業務代表保證的那段額外補足(stub)。你們是否把這些成本從 non-GAAP EPS 與利潤率中排除?我主要是想思考如何建立我對今年以及明年的模型。
And then secondly, in some of those conversations, we've heard if those guys were trued up and given a guarantee this year, it might be more next year they think about, do they stay or not without that guarantee? So -- how are you thinking about the disruptions from the sales transition? Is that more of a '26 impact? Could some of that continue into '27? Just wondering how you think kind of these disruptions gate out between this year and next year?
第二點,在一些對話中我們也聽到,如果今年把那些人調整到位並給了保底,明年他們可能會更多地思考:沒有保底的情況下是否還要留下來。所以——你們如何看待銷售轉型帶來的擾動?這會比較像是 2026 年的影響嗎?是否可能延續到 2027 年?想了解你們如何看待這些擾動在今年與明年之間的分布與消退節奏。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Thank you, Jeff. Look, we go through sales force changes in a variety of ways and magnitudes often. So this is not something we exclude. So going back to why OpEx is slightly higher and what is the EPS going. We're investing in making sure that this works out. So that's number one.
謝謝你,Jeff。你看,我們經常以各種方式與不同幅度進行銷售團隊的變動。所以這不是我們會排除的項目。回到為什麼 OpEx 稍高、以及 EPS 的走勢——我們正在投資以確保這件事能順利落地。這是第一點。
We have offered two-year guarantees that are backed up from a revenue standpoint, in some cases, three-year guarantees. But I would tell you, Jeff, the single largest guarantee that you can offer a sales rep is to let him or her now that it is going to be a long-term future for the employee. So money may cover two to three years. But when you have technology that you're launching like Monogram, when you have the fullest background in orthopaedics, when you're making the investments that we're making, most reps see this as the place to be for the next two years. We can also with jobs every other year.
我們在某些情況下提供了兩年期、並以營收表現作為支撐的保底;也有些情況是三年期保底。但我想告訴你,Jeff,你能給銷售代表的最大保證,是讓他或她知道這份工作有長期的未來。金錢也許能覆蓋兩到三年,但當你推出像 Monogram 這樣的技術、當你在骨科領域擁有最完整的產品組合、當你做出我們正在做的投資時,多數業務代表會把這裡視為未來兩年的最佳去處。我們也可以每隔一年就換工作。
Money is not going to keep you there. But having the feature that they feel they have a Zimmer Biomet was keeping them here. So I will tell you in my conversations we sold reps all over the US, and I'm spending 70% of my time on the road visiting every single territory.
金錢不會讓你一直留下來。但他們覺得在 Zimmer Biomet 擁有的那些特質,才是讓他們留在這裡的原因。所以我會告訴你,在我與全美各地銷售代表的對話中——我有 70% 的時間都在外出,走訪每一個銷售區域。
That's what we hear. If you give me a bank that is robust, if you made me part of something that is going to be great for the long term. Money matters in the short term, but my career is probably more important. Thank you, Jeff.
我們聽到的是:如果你給我一個強大的產品組合(bank),如果你讓我成為一個長期會很成功的事業的一部分。短期來說錢很重要,但我的職涯可能更重要。謝謝你,Jeff。
Operator
Operator
Matthew O'Brien, Piper Sandler.
Matthew O'Brien,Piper Sandler。
Matthew O'Brien - Senior Research Analyst
Matthew O'Brien - Senior Research Analyst
And Suky, best wishes in your future endeavors. Just on the pricing side, Ivan, you mentioned down 40 bps in Q1, but I think you said you're sticking with the down 100 for the year. I guess why stick with the 100 bps should we expect things to get progressively worse throughout the course of the year and then exit the year, down even more than 100 basis points and kind of continue forward at a higher rate than we've seen historically? Or are you just still going to be -- still trying to build in some conservatism with that metrics here this year and then going forward?
Suky,也祝你未來一切順利。Ivan,關於定價方面,你提到第一季下滑 40 個基點,但我記得你也說全年仍維持下滑 100 個基點的假設。我想問為什麼仍維持 100 個基點?我們是否應預期今年接下來會逐步惡化,並在年底時下滑幅度甚至超過 100 個基點,且之後以高於歷史的速度延續?還是你只是想在今年以及往後的這個指標上保留一些保守性?
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Well, first of all, that is the range that we've been given for a while, flat to 100 basis points. In '25, we did better than that. There were a couple of onetime events in international markets. As we enter 2026, we guided flat to 100. We (inaudible) closed the first quarter, but it's a similar answer to revenue and other elements of the guidance. We're going to wait and see there are macro events happening. There are changes in a variety of international markets. There is competitive pressure here in the US. So we're going to wait and see. We like where we are at the end of the first quarter. We'll update you on pricing again in the August call. Thank you.
首先,這個區間我們已經給了一段時間:持平到下滑 100 個基點。2025 年我們做得比這更好,主要是因為國際市場有幾個一次性事件。進入 2026 年時,我們的指引是持平到下滑 100。(聽不清)第一季已經結束,但這與營收及指引中其他要素的回答類似:我們會再觀察,因為宏觀事件正在發生;多個國際市場也在變化;美國這邊也有競爭壓力。所以我們會再等等看。我們喜歡第一季結束時的狀態。我們會在 8 月的電話會議上再次向各位更新定價情況。謝謝。
Operator
Operator
This concludes the question-and-answer portion of today's call. I would like to turn the call over to -- back over to Ivan Tornos for any closing remarks.
今天電話會議的問答部分到此結束。我想把電話交回——交回給 Ivan Tornos,請他做任何結語。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
Sure. I want to thank everybody for joining the call today. And most importantly, I want to thank the Zimmer Biomet team for the strong execution in the first quarter. I give you one word, confidence. Confidence. We -- I am very confident we were in the right direction, not just into 2026, but most importantly, how we are making the company future proof when it comes to the strategy that we have, how we think about operating the company for the future, and the commitments that we're making.
好的。我要感謝大家今天參加電話會議。最重要的是,我要感謝 Zimmer Biomet 團隊在第一季的強勁執行力。我送各位一個詞:信心。信心。我——我非常有信心我們正走在正確的方向上,不僅是邁向 2026,更重要的是,我們如何讓公司在未來策略上具備抗風險能力(future proof),我們如何思考未來的公司營運方式,以及我們正在做出的承諾。
I would like Suky, my friend Suky here, to close the call, given the fact that this is going to be the last time that he represents Zimmer Biomet as the CFO. So Suky?
我想請我的朋友 Suky 在此做結語,因為這將是他最後一次以 CFO 身分代表 Zimmer Biomet。Suky?
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Suketu Upadhyay - Chief Financial Officer, Executive Vice President - Finance, Operations and Supply Chain
Yeah. Thanks, Ivan. So I've learned and taken a lot of away from you over our seven years together. And the one thing that's most impactful is your approach to gratitude. So I'll start there.
好的,謝謝你,Ivan。過去七年與你共事,我從你身上學到並帶走了很多。而最有影響力的一點,是你對「感恩」的態度與做法。所以我就從這裡開始。
I'd like to thank you, the ZB team, the Board, and all of our many partners for an amazing seven years. We've accomplished a lot in a really tough environment. But Ivan, we've built a strong foundation from which to grow. And I'm confident that under your leadership and with the team's execution, you will take ZB to the next level. I wish you all the success, and I'll be [missing you] from the sidelines.
我要感謝你、ZB 團隊、董事會,以及我們眾多合作夥伴,帶來這段精彩的七年。我們在非常艱難的環境中完成了很多事。但 Ivan,我們已建立起一個強健的成長基礎。我也有信心,在你的領導以及團隊的執行下,你會把 ZB 帶到下一個層級。祝你們一切成功,而我會在場邊(想念你們)。
Ivan Tornos - President, Chief Executive Officer, Director
Ivan Tornos - President, Chief Executive Officer, Director
I'm going to miss you. Thank you. Thanks, everybody. Bye-bye.
我會想念你。謝謝。謝謝大家。再見。
Operator
Operator
This concludes today's call. Thank you for your participation. You may now disconnect.
今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。